Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): A multinational study

Psychopharmacology

Volumn 231, Issue 6, 2014, Pages 999-1009

  Hsia, Yingfen ^a,d   Wong, Angel Y S ^a   Murphy, Declan G M ^b   Simonoff, Emily ^b   Buitelaar, Jan K ^c   Wong, Ian C K ^a,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c RADBOUD UNIVERSITY   (Netherlands)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Autism spectrum disorder; Psychopharmacological prescribing; Psychotropic drugs

Indexed keywords

CARBAMAZEPINE; HALOPERIDOL; MELATONIN; METHYLPHENIDATE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; AUTISM; CHILD; DRUG EFFICACY; DRUG SAFETY; EUROPE; HUMAN; NORTH AMERICA; PRESCRIPTION; PRIORITY JOURNAL; SOUTH AMERICA;

ADULT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DATABASES, PHARMACEUTICAL; EUROPE; HUMANS; INTERNATIONALITY; JAPAN; NORTH AMERICA; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; SOUTH AMERICA;

EID: 84896720702     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3263-x     Document Type: Article

References (58)

1. Almandil NB, Wong IC (2011) Review on the current use of antipsychotic drugs in children and adolescents. Arch Dis Child Educ Pract Ed 96(5):192-196
2. Almandil NB, Liu Y, Murray ML, Besag FM, Aitchison KJ, Wong IC (2013) Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs 15(2):139-150
3. Autism Speaks (2009) Autism Speaks announces results reported for the Study of Fluoxetine in Autism (SOFIA). http://www.autismspeaks.org/about-us/ press-releases/autism-speaks-announces-results-reported-study-fluoxetine-autism- sofia. Accessed 13 May 2013
4. Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T (2006) Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 368(9531):210-215 (Pubitemid 44037796)
5. Balkrishnan R, Phatak H, Gleim G, Karve S (2009) Assessment of the use of angiotensin receptor blockers in major European markets among paediatric population for treating essential hypertension. J Hum Hypertens 23(6):420-425
6. Bradley E, Bolton P (2006) Episodic psychiatric disorders in teenagers with learning disabilities with and without autism. Br J Psychiatry 189:361-366 (Pubitemid 44606750)
7. Cadman T, Eklund H, Howley D, Hayward H, Clarke H, Findon J, Xenitidis K, Murphy D, Asherson P, Glaser K (2012) Caregiver burden as people with autism spectrum disorder and attention-deficit/hyperactivity disorder transition into adolescence and adulthood in the United Kingdom. J Am Acad Child Adolesc Psychiatry 51(9):879-888
8. Carbone PS, Farley M, Davis T (2010) Primary care for children with autism. Am Fam Physician 81(4):453-460
9. Coury DL, Anagnostou E, Manning-Courtney P, Reynolds A, Cole L, McCoy R, Whitaker A, Perrin JM (2012) Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics 130(Suppl 2):S69-S76
10. Farrugia JM (2013) The use or misuse of biomedical treatment approaches to autism. Malta Med J 25(1):8-14
11. Fombonne E (2003) The prevalence of autism. JAMA 289(1):87-89
12. Frazier TW, Shattuck PT, Narendorf SC, Cooper BP, Wagner M, Spitznagel EL (2011) Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 21(6):571-579
13. Gringras P, Gamble C, Jones AP, Wiggs L, Williamson PR, Sutcliffe A, Montgomery P, Whitehouse WP, Choonara I, Allport T, Edmond A, Appleton R, MENDS Study Group (2012) Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ 345:e6664
14. Hollander E, Phillips AT, Yeh CC (2003) Targeted treatments for symptom domains in child and adolescent autism. Lancet 362(9385):732-734 (Pubitemid 37101074)
15. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E (2006) Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 9(2):209-213 (Pubitemid 43255834)
16. Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, Feirsen N, Pepa L, Anagnostou E (2010) Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 35(4):990-998
17. Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, Wasserman S, Swanson E, Settipani C (2012) A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry 169(3):292-299
18. King BH, Hollander E, Sikich L et al (2009) Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 66(6):583-590
19. Livermore DM, Reynolds R, Stephens P, Duckworth G, Felmingham D, Johnson AP, Murchan S, Murphy O, Gungabissoon U, Waight P, Pebody R, Shackcloth J, Warner M, Williams L, George RC (2006) Trends in penicillin andmacrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors. Int J Antimicrob Agents 28(4):273-279 (Pubitemid 44425402)
20. Lofthouse N, Hendren R, Hurt E, Arnold LE, Butter E (2012) A review of complementary and alternative treatments for autism spectrum disorders. Autism Res Treat 2012:870391. doi:10.1155/2012/870391
21. Logan SL, Nicholas JS, Carpenter LA, King LB, Garrett-Mayer E, Charles JM (2012) High prescription drug use and associated costs among Medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network. Ann Epidemiol 22(1):1-8
22. MacNeil B, Lopes V, Minnes P (2009) Anxiety in children and adolescents with autism spectrum disorders. Res Autism Spectrum Disord 3:1-21
23. Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE (2008) Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 121(3):e441-e448
24. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48(11):1110-1119
25. Matson JL, Neal D (2009) Seizures and epilepsy and their relationship to autism spectrum disorders. Res Autism Spectrum Disorder 3:999-1005
26. McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, de Soysa R, Taylor E, Williams T, Wong IC (2009) Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 194(3):273-277
27. McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC (2012) Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry 12:219. doi:10.1186/1471-244X-12-219
28. McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J (2011) A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 127(5):e1312-e1321
29. Ming X, Gordon E, Kang N, Wagner GC (2008) Use of clonidine in children with autism spectrum disorders. Brain Dev 30(7):454-460
30. Murray ML, Hsia Y, Glaser K, Simonoff E, Murphy D, Asherson PJ, Eklund H, Wong ICK (2013) Pharmacological treatment prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology (Berl). doi:10.1007/s00213-013-3140-7
31. Myers SM, Johnson CP, American Academy of Pediatrics Council on Children with Disabilities (2007) Management of children with autism spectrum disorders. Pediatrics 120(5):1162-1182 (Pubitemid 350085560)
32. Owen R, Sikich L, Marcus RN, Corey-isle P, Manos G, McQuade RD, Carson WH, Findling RL (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124(6):1533-1540
33. Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP (2006) Physician specialty associated with antipsychotic prescribing for youths in the Texas Medicaid program. Med Care 44(1):87-90 (Pubitemid 43755484)
34. Politte LC, McDougle CJ (2013) Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). doi:10.1007/s00213-013-3068-y
35. Posey DJ, Stigler KA, Erickson CA, McDougle CJ (2008) Antipsychotics in the treatment of autism. J Clin Invest 118(1):6-14
36. Rani F, Murray ML, Byrne PJ, Wong IC (2008) Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121(5):1002-1009
37. Rani FA, Byrne PJ, Murray ML, Carter P, Wong IC (2009) Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary- and tertiary-care settings. Drug Saf 32(4):325-333
38. Rani FA, Byrne P, Cranswick N, Murray ML, Wong IC (2011) Mortality in children and adolescents prescribed antipsychotic medication: a retrospective cohort study using the UK general practice research database. Drug Saf 34(9):773-781
39. Roke Y, van Harten PN, Boot AM, Buitelaar JK (2009) Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 19(4):403-414
40. Roke Y, Buitelaar JK, Boot AM, Tenback D, van Harten PN(2012a) Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol 22(6):432-439
41. Roke Y, van Harten PN, Buitelaar JK, Tenback DE, Quekel LG, de Rijke YB, Boot AM (2012b) Bone mineral density in male adolescents with autism spectrum disorders and disruptive behavior disorder with or without antipsychotic treatment. Eur J Endocrinol 167(6):855-863
42. Roke Y, van Harten PN, Buitelaar JK, Tenback DE, de Rijke YB, Boot AM (2012c) Antipsychotic-induced hyperprolactinemia and testosterone levels in boys. Horm Res Paediatr 77(4):235-240
43. Rosenberg RE, Mandell DS, Farmer JE, Law JK, Marvin AR, Law PA (2010) Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. J Autism Dev Disord 40(3):342-351
44. Rossignol DA, Frye RE (2011) Melatonin in autism spectrumdisorders: a systematic review and meta-analysis. Dev Med Child Neurol 53(9):783-792
45. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114(5):e634-e641 (Pubitemid 41647671)
46. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G (2008) Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 47(8):921-929
47. Souders MC, Mason TB, Valladares O, Bucan M, Levy SE, Mandell DS, Weaver TE, Pinto-Martin J (2009) Sleep behaviors and sleep quality in children with autism spectrum disorders. 32(12):1566-1578
48. Star K, Iessa N, Almandil NB, Wilton L, Curran S, Edwards IR, Wong IC (2012) Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: a case series analysis. J Child Adolesc Psychopharmacol 22(6):440-451
49. The European Medicines Agency (EMA) (2007) Assessment of the paediatric needs psychiatry. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Other/2009/10/WC500004046.pdf. Accessed 03 Aug 2013
50. Volkmar FR (1998) Categorical approaches to the diagnosis of autism: an overview of DSM-IV and ICD-10. Autism 2:45-59
51. Volkmar FR, Reichow B, McPartland J (2012) Classification of autism and related conditions: progress, challenges, and opportunities. Dialogues Clin Neurosci 14(3):229-237
52. Williams K, Wheeler DM, Silove N, Hazell P (2010) Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 8:CD004677. doi:10.1002/14651858.CD004677
53. Williams PG, Woods C, Stevenson M, Davis DW, Radmacher P, Smith M (2012) Psychotropic medication use in children with autism in the Kentucky Medicaid population. Clin Pediatr (Phila) 51(10):923-927
54. Wong IC, Murray ML (2005) The potential of UK clinical databases in enhancing paediatric medication research. Br J Clin Pharmacol 59(6):750-755 (Pubitemid 40838627)
55. Wong IC, Murray ML, Camilleri-Novak D, Stephens P (2004) Increased prescribing trends of pediatric psychotropic medications. Arch Dis Child 89(12):1131-1132
56. Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E (2009) Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY) - a pharmacoepidemiological and qualitative study. Health Technol Assess 13(50):1-120 (iii-iv, ix-xi)
57. World Health Organisation (2013) Application for inclusion to the 19th expert committee on the selection and use of essential medicines: risperidone. Available at: http://www.who.int/selection-medicines/committees/expert/19/ applications/Risperidone-24-A-Ad-Final.pdf. Accessed 03 Aug 2013
58. Zito JM, Safer DJ, de Jong-van den Berg LT, Janhsen K, Fegert JM, Gardner JF, Glaeske G, Valluri SC (2008) A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2(1):26. doi:10.1186/1753-2000-2-26